Drug Details
| General Information of the Drug (ID: DR6904) | ||||
|---|---|---|---|---|
| Name |
Canstatin
|
|||
| Disease | Hepatocellular carcinoma [ICD-11: 2C12] | Investigative | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [1] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PCNA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| In-vivo Model | To establish nude mouse transplantation tumor model, 0.2 ml of HepG2 cells (1 * 107/ml) were injected subcutaneously in the right axilla of mice. | |||||
| Experimental
Result(s) |
Combined canstatin and ATO significantly inhibited cell proliferation, migration and adhesion abilities, and promoted cell apoptosis, and inhibited tumor growth, thus suppressed the progression of HCC. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | HIV Protease (HIV PR) | Molecule Info | [2] | |
